NervGen Posts C$0.32 Q2 Loss as Warrant Charge Hits Bottom Line
NGEN sits 16% above its 52-week low of $1.58.
Summary
NervGen reported a Q2 2026 net loss of C$29.2M, or C$0.32 per share, driven largely by a non-cash warrant derivative charge. The loss is wider than typical operating burn and reflects the accounting impact of the company's recent financing activity. This follows the $60M public offering in May and the establishment of a $50M ATM program in July, both aimed at funding the NVG-291 clinical program. The company had previously warned that cash reserves were only sufficient for a limited period, so the capital raises were expected. The key question for investors is whether the underlying operating loss, excluding the warrant charge, remains within the guided range and whether the cash runway has been extended as planned.
At the time of this announcement, NGEN was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $144.7M. The 52-week trading range was $1.58 to $6.30. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.